Variable | Â |
---|---|
Airleak | Â |
   Air Leak before HFOV | 22/102 (21.6 %) |
   Persistent air Leak during HFOV | 5/22 (22.7 %) |
   New air leak during HFOV | 2/80 (2.5 %) |
Co-treatment (Some patients received more than one co-treatment) | Â |
   Nitric oxide | 21/102 (20.6%) |
   MARS | 1/102 (0.98%) |
   Steroids | 19/102 (18.6%) |
   Prone position | 20/102 (19.6%) |
   rhAPC | 3/102 (2.9%) |
   None | 56/102 (54.9%) |
Mortality | Â |
   Post HFOV | 49/102 (48%) |
   ICU discharge | 62/102 (60.8%) |
   30-day | 57/102 (55.9%) |
Cause of death at 30-days | Â |
   Withdrawal of treatment | 22/57 (38.6%) |
   >2 organ failure | 20/57 (35.1%) |
   Cardiac arrhythmia | 6/57 (10.5%) |
   Refractory hypoxia | 4/57 (7%) |
   Sepsis | 3/57 (5.3%) |
   Profound hypotension | 2/57 (3.5%) |